<DOC>
	<DOCNO>NCT01543802</DOCNO>
	<brief_summary>The purpose study examine short-term treatment pazopanib , oral drug inhibit growth blood vessel , reduce metabolism soft-tissue sarcoma thus facilitate resection give prior surgery . Moreover , study ass prognostic predictive value several new biomarkers ( endothelial progenitor cell , soluble vascular epithelial growth factor ) ,</brief_summary>
	<brief_title>Study Preoperative Therapy With Pazopanib ( Votrient® ) Treat High-risk Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>1 . Written inform consent prior performance studyspecific procedures assessment must willing comply treatment followup . 2 . Age ≥ 18 year legal age consent different 18 year . 3 . Nonmetastatic primary tumor locoregional recurrence histologically confirm highrisk ( G2/3 , diameter ≥5 cm ) soft tissue sarcoma ( STS ) location ( extremity , girdle , trunk , retroperitoneum ) ; metachronous solitary metastasis STS surgical resection plan accord individual choice multidisciplinary treatment team ( grade size restriction apply metastasis ) . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . Measurable disease accord RECIST 1.1 6 . Resectable solitary tumor , assess investigator base stag exam ( CT scan chest , CT MRI abdomen , MRI limb case extremity STS ) . 7 . Adequate organ system function 8 . Women childbearing potential must negative serum pregnancy test within 14 day first dose study treatment agree use effective contraception , study surgery perform . 9 . Female subject lactate discontinue nursing prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug . 1 . The following tumor type ineligible Embryonal rhabdomyosarcoma Chondrosarcoma Osteosarcoma Ewing tumor / PNET Gastrointestinal stromal tumor Dermofibromatosis sarcoma protuberans Inflammatory myofibroblastic sarcoma Malignant mesothelioma 2 . Prior malignancy . 3 . History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis . 4 . Prior concurrent systemic chemotherapy molecularly target therapy STS malignancy within five year study entry . 5 . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding . 6 . Clinically significant gastrointestinal abnormality may affect absorption investigational product 7 . Corrected QT interval ( QTc ) &gt; 480 msec ( calculation accord Bazett ) . 8 . Presence uncontrolled infection . 9 . History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA ) 10 . Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥140 mmHg diastolic blood pressure ( DBP ) ≥ 90mmHg ] . 11 . Cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . 12 . Major surgery trauma within 28 day prior first dose investigational product and/or presence nonhealing wound , fracture , ulcer ( procedure catheter placement consider major surgery ) . 13 . Evidence active bleeding bleed diathesis . 14 . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel increase risk pulmonary hemorrhage . 15 . Recent hemoptysis ( ½ teaspoon red blood within 8 week first dose study drug ) . 16 . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . 17 . Inability unwillingness discontinue use prohibit medication least 14 day five halflives drug ( whichever longer ) prior first dose investigational product duration study . 18 . Treatment follow therapy : radiation therapy , surgery target lesion study incisional biopsy , tumor embolization , prior first dose pazopanib OR chemotherapy , immunotherapy , biologic therapy , antiangiogenic therapy , investigational therapy hormonal therapy , target lesion study , prior first dose pazopanib OR chemotherapy , immunotherapy , biologic therapy , antiangiogenic therapy , investigational therapy hormonal therapy , target lesion / disease , within 14 day five halflives drug ( whichever longer ) prior first dose pazopanib 19 . Administration nononcologic investigational drug within 30 day 5 half life whichever longer prior receive first dose study treatment . 20 . Any ongoing toxicity prior anticancer therapy &gt; grade 1 and/or progress severity , except alopecia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>soft-tissue sarcoma</keyword>
	<keyword>pazopanib</keyword>
	<keyword>antiangiogenetic treatment</keyword>
	<keyword>endothelial progenitor cell</keyword>
	<keyword>preoperative therapy</keyword>
</DOC>